MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Paranoid Schizophrenia Clinical Trial

Official title:
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the safety and effectiveness of an investigational drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00506077
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 2
Start date	December 2007
Completion date	October 2008

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00482430` - MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)	Phase 2
	Active, not recruiting	`NCT04902066` - Face Your Fears: Cognitive Behavioural Virtual Reality Therapy for "Paranoia".	N/A